Analyst Activity – HC Wainwright Reiterates Buy on BioCryst Pharmaceuticals (NASDAQ:BCRX)

Analyst Ratings For BioCryst Pharmaceuticals (NASDAQ:BCRX)

Story continues below

Today, HC Wainwright reiterated its Buy rating on BioCryst Pharmaceuticals (NASDAQ:BCRX) with a price target of $10.00.

Some recent analyst ratings include

  • 1/23/2018-HC Wainwright Reiterated Rating of Buy.
  • 1/2/2018-Royal Bank of Canada Upgrade from a “Sector Perform ” rating to a ” Outperform” rating.
  • 12/20/2017-Barclays initiated coverage with a Equal Weight rating.
  • 9/6/2017-Jefferies Group Upgrade from a “Hold ” rating to a ” Buy” rating.
  • 9/5/2017-Piper Jaffray Companies Reiterated Rating of Overweight.
  • 8/8/2017-Noble Financial Reiterated Rating of Buy.

Recent Insider Trading Activity For BioCryst Pharmaceuticals (NASDAQ:BCRX)
BioCryst Pharmaceuticals (NASDAQ:BCRX) has insider ownership of 5.60% and institutional ownership of 84.69%.

  • On 11/13/2017 William P Sheridan, CMO, sold 64,310 with an average share price of $4.72 per share and the total transaction amounting to $303,543.20.
  • On 9/18/2017 Fred E Cohen, Director, sold 54,250 with an average share price of $5.42 per share and the total transaction amounting to $294,035.00.
  • On 3/20/2017 Thomas R Staab II, CFO, sold 3,250 with an average share price of $9.20 per share and the total transaction amounting to $29,900.00.
  • On 3/10/2017 Thomas R Staab II, Insider, sold 3,250 with an average share price of $9.06 per share and the total transaction amounting to $29,445.00.
  • On 3/8/2017 Thomas R Staab II, Insider, sold 6,500 with an average share price of $8.43 per share and the total transaction amounting to $54,795.00.
  • On 3/6/2017 Thomas R Staab II, Insider, sold 3,250 with an average share price of $7.90 per share and the total transaction amounting to $25,675.00.
  • On 12/19/2016 Thomas R Staab II, Insider, sold 3,250 with an average share price of $7.45 per share and the total transaction amounting to $24,212.50.

Recent Trading Activity for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Shares of BioCryst Pharmaceuticals closed the previous trading session at 5.55 up +0.23 4.32% with 309765 shares trading hands.

An ad to help with our costs